Tasigna (nilotinib) - Possible Risk Of Developing Atherosclerosis-related Conditions - For The Public

Recall Summary Tasigna (nilotinib), a medication used to treat certain types of leukemia, is being reviewed due to a possible risk that it may increase the likelihood of developing atherosclerosis-related conditions (narrowing of arteries). This recall affects all patients in Canada who are currently taking or have taken this medication.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2013-04-12

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/36a0cb3a-0c26-483b-9f02-a8c8ac1cb946